Kinsenoside prevents ovariectomy-induced bone loss and suppresses osteoclastogenesis by regulating classical NF-κB pathways

34Citations
Citations of this article
27Readers
Mendeley users who have this article in their library.

Abstract

Kinsenoside is able to improve bone turnover rate in ovariectomized (OVX) mice. In vitro analysis shows that kinsenoside antagonizes osteoclast development and bone resorption. Introduction: Kinsenoside, the main active compound of the traditional Taiwanese herb Anoectochilus formosanus, has an antiinflammatory effect. This study investigates whether kinsenoside inhibits osteoporosis and osteoclastogenesis. Methods: OVX mice were used to examine the antiosteoporotic activity of kinsenoside. The trabecular bone microarchitecture was assessed by microcomputed tomography. In vitro experiments were performed to determine the mechanisms of the antiosteoporotic effects of kinsenoside. Results: Microcomputed tomography scanning showed that kinsenoside suppresses bone loss in OVX mice. Kinsenoside decreases plasma CTx concentration. Reverse transcription polymerase chain reaction (RT-PCR) analysis also showed that kinsenoside reduces the femoral mRNA expression of tartrate-resistant acid phosphatase (TRAP) and matrix metalloproteinase-9 (MMP-9). Kinsenoside inhibits osteoclast formation in bone marrow cells (BMs) and RAW 264.7 cells. Western blot was used to analyze osteoclast-associated signaling pathways in RAW 264.7 cells. Results show that kinsenoside does not inhibit IKK phosphorylation but suppresses the phosphorylation of IκBα and p65. Kinsenoside significantly inhibits the RANKL induction of IKK activity. Kinsenoside inhibits the RANKL-triggered nuclear translocations of NF-κB and nuclear factor of activated T cells c1 (NFATc1). RT-PCR was used to analyze osteoclast precursor fusion and resorption-associated gene expression in BMs. Kinsenoside inhibits the expression of cathepsin K (CAK), dendritic cell-specific transmembrane protein, MMP-9, and TRAP. Conclusions: Kinsenoside inhibits osteoclastogenesis from macrophages by attenuating RANKL-induced NF-κB and NFATc1 activities, which in turn, prevents bone loss from OVX mice. © 2012 The Author(s).

References Powered by Scopus

Guidelines for assessment of bone microstructure in rodents using micro-computed tomography

3536Citations
N/AReaders
Get full text

Bone resorption by osteoclasts

3358Citations
N/AReaders
Get full text

Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts

2191Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Medicinal orchids of Asia

164Citations
N/AReaders
Get full text

Therapeutic potential and outlook of alternative medicine for osteoporosis

137Citations
N/AReaders
Get full text

Pharmacological agents and natural compounds: Available treatments for osteoporosis

97Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Hsiao, H. B., Lin, H., Wu, J. B., & Lin, W. C. (2013). Kinsenoside prevents ovariectomy-induced bone loss and suppresses osteoclastogenesis by regulating classical NF-κB pathways. Osteoporosis International, 24(5), 1663–1676. https://doi.org/10.1007/s00198-012-2199-z

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 14

70%

Researcher 6

30%

Readers' Discipline

Tooltip

Medicine and Dentistry 10

53%

Agricultural and Biological Sciences 6

32%

Biochemistry, Genetics and Molecular Bi... 2

11%

Materials Science 1

5%

Save time finding and organizing research with Mendeley

Sign up for free